Wednesday, 3 October 2018

Carcinoid Tumor Market 2018 Global Industry Key Players, Share, Trend, Segmentation and Forecast to 2023

Market Scenario:
Carcinoid tumor is a type of the neuroendocrine tumor. A neuroendocrine tumor develops in the body’s neuroendocrine system, which is made up of cells that are a combination of hormone-producing endocrine cells and nerve cells. The most common site of carcinoid tumors is GI (gastrointestinal) tract and lungs. The other sites for the development of the carcinoid tumors is inclusive of the pancreas, testicles, and ovaries. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract. Moreover, it was also estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung. Thus, the prevalence of the carcinoid tumor is expected to drive the market. In 2016, American Society of Clinical Oncology (ASCO) published a report stating that the people who were diagnosed with carcinoid tumor were in their early 60s. Additionally, according to the report of WHO published in 2015, the geriatric population is expected to double and reach 2.1 billion by 2050. Thus, the growing geriatric population along with rising healthcare expenditure is set to boost the market growth during the forecast period. However, lack of awareness, treatment cost and related side effects may restrain the market growth during the forecast period. 
The global carcinoid tumor market is expected to grow at an approximate of CAGR of 10.5% during forecast period. 
Key Players
  • Novartis AG (Europe)
  • Amgen Inc. (U.S.)
  • Boehringer Ingelheim GmbH (Europe)
  • AVEO Pharmaceuticals, Inc. (U.S.)
  • Chiasma, Inc. (U.S.)
  • Aegis Therapeutics, LLC (U.S.)
  • CRINETICS PHARMACEUTICALS (U.S.)
  • Delcath Systems Inc. (U.S.)
  • Exelixis, Inc. (U.S.)
Regional Analysis
America dominates the global carcinoid tumor market owing to a well-developed healthcare sector and huge patient population. Apart from this, increasing healthcare expenditure and presence of developed economies within the region are adding fuel to the growth of the market in America.
Europe is the second leading region in the global carcinoid tumor market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development are projected to drive the market. According to the National Health Service in 2015, each year about 1,200 people diagnose with carcinoid tumor in the UK.
Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies like India and China, and the presence of huge opportunity in the market. Moreover, there are huge opportunities within the region for the growth of the untapped market.
On the other hand, the Middle East & Africa accounts the least share of the global carcinoid tumor market due to presence of poor economy, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Segmentation
The global carcinoid tumor market is segmented on the basis of site, diagnosis, treatment, and end users.
On the basis of site, the market is segmented into gastrointestinal, lung, and others. Furthermore, the gastrointestinal segment is sub-segmented into rectum, small intestine, appendix, and others. The lung segmented is sub-segmented into typical, atypical, and others.
On the basis of diagnosis, the market is segmented into serology, imaging, biopsy, and others. The serology segment is sub-segmented into blood test, urine test, molecular test, and others. The imaging segment is sub-segmented into X-ray, CT scan, PET scan, and others.
On the basis of treatment, the market is segmented into surgery, chemotherapy, radiotherapy, and others. The surgery segment is sub-segmented into local excision, radiofrequency ablation (RFA), and others.
On the basis of end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Global Molecular Modelling Market Analysis 2018 Forecasts to 2023

Market Scenario
Molecular modeling has become a valuable and essential tool in the medicinal chemistry for the drug design process. It describes generation, manipulation or representation of three-dimensional structures of molecules and their associated physic-chemical properties. The method is used in drug design, computational biology, computational chemistry, and materials science. It involves wide range of computerized techniques based on theoretical chemistry methods and experimental data to analyze the biological and molecular property.
The major driving factor for the market are increasing investment of biotechnology and pharmaceutical industries in R&D, increasing prevalence of different diseases, and rising need for the better drug treatments. According to the World Health Organization (WHO), chronic diseases, such as heart disease, respiratory diseases, cancer, stroke, and diabetes are the leading cause of mortality across the globe, which represents about 60% of all deaths. Additionally, 80% of the chronic disease deaths occur in low and middle income countries. Moreover, technological advancements, growth in the biology and biosimilars markets, increasing need for the cost effective treatment, and increasing government support for research & development expected to fuel the market growth during the forecast period. However, high cost of the research & development may hamper the market growth during the corresponding period.
The global molecular modelling market is expected to grow at a CAGR of ~ 15.4 % during the forecast period 2017-2023.
Segmentations
The global molecular modelling market has been segmented on the basis of approach, application, products, and end user.
On the basis of approach, the market is segmented into molecular mechanics approach, and quantum chemistry approach.
On the basis of product, the market is segmented into instruments, reagents, kits, and others.
On the basis of application, the market is segmented into drug development, drug discovery, and other application. The drug discovery is further segmented into direct drug design, indirect drug design, and molecular mimicry. The direct drug design is sub-segmented into lead identification, target identification, and others. The indirect drug design is sub-segmented into pharmacophore, quantitative structure-activity relationships (QSAR), and others.
On the basis of end user, the market is segmented into pharmaceutical & biotechnological companies, research organizations, and others.
Regional Analysis
The Americas dominates the global molecular modelling market owing to well-developed technology, increasing prevalence of the people suffering from cardiovascular diseases, and increasing government support for research & development. Furthermore, high healthcare expenditure and increasing R&D activities have fuelled the growth of the market in this region.
Europe holds the second position in the global molecular modelling market, which is followed by Asia Pacific. It is expected that the government support for research & development and availability of funds for research will drive the market. Asia Pacific is the fastest growing molecular modelling market due to the presence of rapidly growing economy, developing healthcare technology, increasing healthcare expenditure, and huge patient pool.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.
Major Key Players for Molecular Modelling Market
Some of key the players in the market are Fisher Scientific Company LLC. (US), Indigo Instruments (US), Simulation Plus (US), Certara, L.P. (US), Dassault Systèmes (France), Advanced Chemistry Development (Canada), Schrödinger, LLC (US), Genedata AG (Switzerland), Chemical Computing Group ULC (Canada), Physiomics PLC (UK), and Entelos, Inc. (US).
Detailed Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs Of The Market
13.2 Key Companies To Watch
13.3 Prediction Of Molecular Modelling Industry
14 Appendix
...Continued

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Hirsutism Treatment Market: Global Analysis, Industry Growth, Current Trends and Forecast till 2023

Market Scenario:
Hirsutism is a condition of excessive, unwanted, and male-pattern hair growth in women. Hirsutism results in unwanted hair growth on body areas such as face, stomach, back, and chest. About 5% of US women have hirsutism.
Increasing procedures, growing awareness of treatments, increasing personal care expenditure, and technological advancement are major factors for the market growth. Increasing R&D and new product development are also important factors for market growth.
Global Hirsutism treatment market is expected to grow at the CAGR of ~13.6% during the forecast period and is estimated to reach USD 5295.0 million by 2023.
Key players
  • AbbVie Inc. (US)
  • Allergan (Republic of Ireland)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (US)
  • Jubilant Cadista (US)
  • Pfizer Inc. (US)
  • Sun Pharmaceutical Industries Ltd. (India)
Segments:
Global hirsutism treatment market has been segmented on the basis of type which comprises of idiopathic hirsutism, secondary hirsutism, and others.
On the basis of diagnosis, the market is segmented into blood tests, imaging tests, physical examination, and others. Blood tests sub-segmented into testosterone level test, DHEA-sulfate test, and others. Imaging test sub-segmented into ultrasound, CT scan, and others. Physical examination sub-segmented into inspection, auscultation, palpation and percussion, and others.

On the basis of treatments, the market has been segmented into medications, procedures, and others. Medication is sub-segmented into oral contraceptives, anti-androgens, topical cream, and others. Procedures include electrolysis, laser therapy, and others.

On the basis of end user, it is segmented into hospitals and clinics, medical research centers, academic institutes, and others.

Regional analysis of global Hirsutism treatment market:
Considering the global scenario of the market, America is holding the largest market share. The Americas are second largest hirsutism treatment market, especially developed North America region is holding the largest market share not only in America but also in global hirsutism treatment market. While UK is believed to be the fastest growing market for hirsutism treatment in European region. Factors like technological advancement, and increasing demand for treatments are leading the growth for this region. Europe is the second largest market for hirsutism. Due to Increasing awareness, rising healthcare expenditure, availability of affordable healthcare facilities, Asia Pacific is fastest growing region in global hirsutism market. Middle East and Africa contributes least market share and expected to grow slower than global average growth rate.
Detailed Table of Contents:
1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor Analysis
5.1 Value Chain Analysis
5.2 Porters Five Forces
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
...Continued

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

India CRO Market Global Sales, Revenue, Price and Gross Margin Forecast To 2023

Market Synopsis of India CRO Market:
A Contract Research Organization (CRO) offers outsourced services to support R&D functions for pharmaceutical, biotechnology, and health companies. The CRO’s service ranges from different research and development activities such as drug discovery, pre-clinical (pre-human in-vitro and in-vivo animal research model) and clinical (in-human) testing. Moreover, the contract research organizations have gained importance in the recent years due to the development of biotechnology and pharmaceutical sectors.
India has rapidly become one of the preferred destinations for clinical trials owing to its large heterogeneous patient pool, rapidly transforming healthcare market, highly educated physicians and cost competitiveness propels the market growth. In addition, increased investment from foreign companies as well as local market players either individually or in collaboration is likely to boost the market growth during the forecast period. Further, emerging research areas such as diagnostic research are expected to fuel the India CRO market.
The India CRO market restraints are rising concern for security especially data security and patient security in clinical trials, lack of collaboration between universities and industry. Further, the compromises done by some India CROs on ethical and technical standards are the major market threat.
The India CRO Market growth is expected to flourish at a CAGR of 12.0% during the forecast period.
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Key Players for India CRO Market: 
  • Quintiles IMS Holdings, Inc.
  • Pharmaceutical Product Development
  • Siro Clinpharm
  • GVK Bio
  • Clininvent
  • CliniRX Tangent Research
  • Ecron Acunova
  • Ace Biomed Pvt. Ltd.
  • Actimus Biosciences Pvt. Ltd.
  • Alkem Laboratories Ltd.
  • Actis Biologics Pvt Ltd.
Regional Analysis of India CRO Market:
The healthcare sector of India is divided between differential geographic regions and states. The South India and western India account for a major share of the Indian CRO market. However of late the CRO industry is shifting to the North. The reasons for this shift is the concentration of regulatory authority such as Director Controller General of India (DCGI) office, Indian Council of Medical Research (ICMR), Directorate General of Foreign Trade (DGFT), Department of Biotechnology (DBT) etc. Also the costs are lower in North India and the genetic pool is more diverse.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/2927
Detailed Table of Contents:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
List Of Tables
Table 1 India Cro Market, 2013-2022 (Usd Million)
Table 2 India Cro Market, By Service Type, 2013-2022 (Usd Million)
Table 3 India Cro Market, By Therapeutic Application, 2013-2022 (Usd Million)
Table 4 India Cro Market, By End User, 2013-2022 (Usd Million)
Table 5 India Cro Market, By Region, 2013-2022 (Usd Million)
List Of Figures
Figure 1 Research Process
Figure 2 Porters Five Forces Model
Figure 3 India Cro Market, By Service Type
Figure 4 India Cro Market, By Therapeutic Application
Figure 5 India Cro Market, By End User
Figure 6 India Cro Market, By Region
Figure 7 India Cro Market: Company Share Analysis, 2016 (%)
...Continued
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Augmented Bone Graft Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Augmented Bone Graft Market Research Report- Global Forecast till 2023” Gives industry size, top players and worldwide demand
According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.
Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.
Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.
The Global market of Augmented Bone Graft is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.
There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.
Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.
Additionally, stringent regulations obstruct the growth of bone grafts market and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.
Segmentation
The Augmented Bone Graft is segmented on the basis of products, application, and end-users.
On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.
On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion
On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.
Competition Analysis
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players. For example, the Stryker Corporation, in order to enhance its business, acquired companies such as Novadaq Technologies Inc. in 2017, Stanmore Implants Worldwide Limited, Physio-Control International Inc, & Vertebral compression fracture portfolio from BD in 2016; and some other companies in the recent past.
Some of key the players in the Global Augmented Bone Graft Market are
  • Zimmer Holdings, Inc.
  • BioMimetic Therapeutics LLC
  • Wright Medical Technology, Inc.
  • Stryker Corporation, Smith & Nephew Plc
  • RTI Surgical, Inc.,
  • Olympus Biotech Corporation
  • NuVasive, Inc.
  • NovaBone Products LLC
  • Medtronic, Inc.
  • LifeNet Health, Inc.
  • Integra LifeSciences Holdings Corporation
  • Exactech, Inc.
  • DePuy Spine, Inc.
  • Synthes Inc.
  • DePuy Synthes Companies
  • Biomet, Inc.
Regional Analysis
The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.
For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.
Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.
Detailed Table of Contents:
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
...Continued
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Acute Intermittent Porphyria Market 2018 Global Industry Key Players, Share, Trend, Segmentation and Forecast to 2023


Market Scenario
Porphyria is a disorder that occurs when there is a build-up of the chemicals in the body that produce a substance called porphyrin. Acute intermittent porphyria (AIP) is a genetic metabolic disorder is one of the 8 types of porphyria. It affects the production of heme, the oxygen-binding prosthetic group of hemoglobin. Children have a 50% chance of inheriting any of the 8 different types of porphyria if their parents have the disorder.
Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.

The acute intermittent porphyria market growth is majorly attributed to the increasing prevalence of the metabolic disorders, gastrointestinal issues, urinary tract issues, and healthcare insurance coverage. Moreover, increasing geriatric population will drive the market growth.
According to the Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia is likely to help the growth of the market over the forecast period.
According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
According to the American Liver Foundation, there is an increasing the prevalence of liver disease in the U.S. from then last few years. It further stated that at least 30 million people have some form of liver disease.
However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.
The global acute intermittent porphyria market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023. 
Segmentations
The global acute intermittent porphyria market is segmented on the basis by diagnosis, by treatment, and by end user.
On the basis of diagnosis, it is segmented into blood test, urine test, serum test, DNA test, and others.  
On the basis of treatment, it is segmented into gonadotropin-releasing hormone analogues, prophylactic hematin infusions, and others.
On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.
Regional Analysis
The Americas dominate the global acute intermittent porphyria market owing to well-developed technology, increasing patient with genetic metabolic disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global acute intermittent porphyria market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.  
Asia Pacific is the fastest growing acute intermittent porphyria market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acute intermittent porphyria in the region.
On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Key Players
Some of key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc.  (U.S.), Siemens AG (U.S.),  ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc. (U.S.).

Detailed Table of Contents:
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
...Continued

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com